Document Detail

The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients--a European perspective.
MedLine Citation:
PMID:  16115174     Owner:  NLM     Status:  MEDLINE    
Glaucoma is a condition affecting one or both eyes with raised intraocular pressure (IOP). IOP should be reduced to prevent progression of visual field loss. This study investigates the cost-effectiveness of bimatoprost compared with latanoprost as first-line monotherapies in the treatment of glaucoma in Austria, Finland and France. On the basis of a single multicentre, randomised, investigator-masked controlled trial, a 6- and 12-month cost-effectiveness model was designed following the treatment recommendations from the European Glaucoma Society. Treatment changes due to insufficient IOP reduction and adverse events were included. The cost-effectiveness analysis showed that the need for adjunctive therapy was the major cost driver. On the basis of evidence from the randomised, investigator-masked clinical trial (RCT), the cost-effectiveness analysis found that bimatoprost was a cheaper and a more effective treatment strategy compared with latanoprost. This was true for all three countries and all IOP targets between 13 and 20 mmHg. The cost-effectiveness result may be generalised to a European setting and perspective.
E Tuil; A B Hommer; P B Poulsen; T L Christensen; P Buchholz; J Walt; S Holmstrom
Related Documents :
17293784 - Management of glaucoma in patients with nanophthalmos.
8985544 - Surgery for refractory glaucoma.
18691444 - Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy...
16983524 - Long-term results of surgery in childhood glaucoma.
22775764 - Immunohistochemical, tomographic, and histological study on onlay bone graft remodeling...
25446484 - Ventral segment-preserving right hepatectomy in patients with hepatocellular carcinoma.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of clinical practice     Volume:  59     ISSN:  1368-5031     ISO Abbreviation:  Int. J. Clin. Pract.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-08-23     Completed Date:  2006-02-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9712381     Medline TA:  Int J Clin Pract     Country:  England    
Other Details:
Languages:  eng     Pagination:  1011-6     Citation Subset:  IM    
CHNO des Quinze Vingts, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / adverse effects,  economics*,  therapeutic use
Chemotherapy, Adjuvant / economics
Cloprostenol / analogs & derivatives
Cost-Benefit Analysis
Drug Costs
Glaucoma / drug therapy*
Lipids / adverse effects,  economics*,  therapeutic use
Models, Economic*
Ophthalmic Solutions
Prostaglandins F, Synthetic / adverse effects,  economics,  therapeutic use
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Amides; 0/Antihypertensive Agents; 0/Lipids; 0/Ophthalmic Solutions; 0/Prostaglandins F, Synthetic; 0/bimatoprost; 130209-82-4/latanoprost; 40665-92-7/Cloprostenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Open tension-free Cooper ligament repair for femoral hernia.
Next Document:  Unscheduled healthcare resource use among asthma patients receiving low-dose inhaled corticosteroids...